Treatment of tuberculosis: Use of active pharmaceuticals

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 1, 2008, Pages 34-44

  Samad, Abdus ^a   Sultana, Yasmin ^a   Akhter, Md S ^b   Aqil, Mohammad ^a  

^a HAMDARD UNIVERSITY   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Antimycobacterial agents; Mycobacterium; Natural products; Synthetic and semi synthetic products; Tuberculosis

Indexed keywords

ADHATODA VASICA EXTRACT; AMINOSALICYLIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BIDENS PILOSA EXTRACT; CIPROFLOXACIN; CYCLOSERINE; ERYTHROMYCIN; ETHAMBUTOL; GINSENG EXTRACT; ISONIAZID; MANGIFERA INDICA EXTRACT; NALIDIXIC ACID; OFLOXACIN; OXAZOLIDINEDIONE DERIVATIVE; PLANT EXTRACT; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROKITAMYCIN; ROXITHROMYCIN; SANTOLINA CHAMAECYPARISSUS EXTRACT; SAUSSUREA LAPPA EXTRACT; SOLIDAGO CANADENSIS EXTRACT; SPIRAMYCIN; STREPTOMYCIN; THIOLACTOMYCIN; TIOCARLIDE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG SYNTHESIS; EPIGASTRIC PAIN; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; LIP DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; NONHUMAN; PATENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; URTICARIA; VISUAL IMPAIRMENT;

ANTITUBERCULAR AGENTS; HUMANS; PLANT EXTRACTS; TUBERCULOSIS;

EID: 38949203766     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108783413209     Document Type: Review

References (104)

1. World Health Organization. Global Tuberculosis Control, WHO Report 2001, (b) World Health Organization. Geneva, Switzerland, WHO/CDS/TB/2001, 285 (c) World Health Organization. Tuberculosis Fact Sheet No. 104. 2000.
2. Mooran N. World Health Organization issues another gloomy tuberculosis report. Nat Med 1996; 2: 377.
3. Snider DE, Raviglione M, Kochi A. Tuberculosis. In: bloom Br, editor. Pathogenesis, protection & control. Washington DC: Am Soc Micobiology 1994; 2-11.
4. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: Estimated incidence, prevalence and mortality by country. WHO global surveillance and monitoring project. J Am Med Assuc 1999; 282: 677-686.
5. Farmer P, Bayona J, Beccera M, et al. The dilemma of MDR TB in global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
6. Dony JF, Ahmad J, Khen TY. Epidemiology of tuberculosis and leprosy, Sabah, Malaysia. Tuberculosis 2004; 84: 8-18.
7. World Health Organization. TB a global emergency, WHO TB programme. Geneva: Switzerland 1994; 177: 1-28.
8. Dhingra VK, Rajpal S, Tanega DK, Kalra D, Malhotra R. Health care seeking pattern of tuberculosis patients attending an urban TB clinic in Delhi. J Commun Dis 20002; 34(3): 185-192.
9. Singh MM. Tuberculosis- Triumph and tragedy. J Indian Med Ass 2003; 101 (3): 190-194.
10. Frame AD, Rios OE, De Jesus L, Ortiz D, Pagan J, Mendez S. Plants from Puerto Rico with Antimycobacterium tuberculosis properties. P R Health Sci J 1998; 17: 243-252.
11. Dannenberg A Jr. Immunopathogenesis of pulmonary tuberculosis Hosp Pract 1993; 28; 51-58.
12. Daniel TM, Bates JH, Downes KA. History of tuberculosis In: Bloom BR, editor. Tuberculosis: Pathogenesis, protection and control Washington DC ASM Press. 1994; 13-24.
13. Nardell E. Pathogensis of tuberculosis. In: Reichman LB, Herchfield E, editor. Lung biology in health and disease. New York: Marcel Decker Inc 1993; 103-123.
14. Schemitt E, Meuret G, Stix E. Monocyte recruitment in tuberculosis and sarcoidosis. Br J Heamatol 1997; 35 11-17.
15. Spencer H. Pathology of lung Oxford Pergmon Press 1985; 4-1.
16. Davidson PT, Le HQ. Drug treatmenty of tuberculosis - 1992. Drugs 1992; 43: 651-673.
17. Tillotson GS. Tuberculosis- New aspects of chemotherapy. J Med Microbiol 1996; 44: 16-20.
18. Grange J. Antimycobacterial agents. In: O'Grady F, Lambert HP, Finch RG, Greenwood D, editors. Antibiotics and chemotherapy, 7th Ed. Edinburg: Churchil Living stone 1997; 449-512.
19. Greenwood D. Historical introduction. In: O'Grady F, Lambert HP, Finch RG, Greenwood D. Antibiotics and chemotherapy, 7th Ed. Edinburg: Churchil Living stone 1997; 2-9.
20. Mitchison D, Nunn P. Influence of initial drug resistance on the response to short course therapy of pulmonary tuberculosis. Am Rev Resp Dis 1986; 133: 423-430.
21. Duarte, D.M.N.M., Goncalves, D.M.D.C., Martins, M.C.M., Preto, X.L.M.A, Vidal, D.B.M., Luna-Herrera, J., Reyes, R.E.D.C.: EP1803463 (2007).
22. Protopopova, M.N., Einck, L., Nikonenko, B., Chen, P.: W007005896 ( 2007).
23. Barluenga, M.J., Aznar, G.F., Cabal, N.M.-P., Garcia, D.A.-B., Valdes, G.C.: EP1783129 (2007).
24. Blanchard J. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996; 65: 215-239.
25. Phillips I, Shannon KP. Aminoglycosides and aminocyclitols. In In: O'Grady F, Lambert HP, Finch RG, Greenwood D, editors. Antibiotics and Chemotherapy, Edinburg: Churchil Living stone 1997; 164-201.
26. Zhang Y, Heym B, Allen B, Young D, Cole ST. The catalase peroxidase gene and isoniazid resistance of Mycobactrium tuberculosis. Nature 1992; 358: 591-593.
27. Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase- peroxidase gene, kat G, are associated with isoniazid reistance in Mycobacterium tuberculosis. Mol Microlbiol 1995; 15: 235-245.
28. Mdluli K, Slayden RA, Zhu Y, et al. Inhibition of c Mycobacterium tuberculosis B ketacyl ACP synthase by isoniazid. Science 1998; 280: 1608-16110.
29. Parneti F, Lancini G, O'Grady F, Lambert HP, Finch RG, Greenwood D. In: Antibiotics and Chemotherapy, Edinburg: Churchil Living stone 1997; 453-459.
30. Gale EF, Cundliffe E, Reynolds PE, Richmond MH, Warning MJ. In: The molecular basic of antibiotic action, London-John Wiley and Sons. 1981.
31. Saito H, Tomioka H, Sato K, et al. in vitro Antimycobacterial activity of newly synthesized benzoxazinorifamycins. Antimycrobial Agents Chemther 1991; 35: 542-547.
32. Rastogi N, Labrousse V. Extracellular and intracellular activity of clarithromycin used alone and in association with ethambutol and rifamycin against Mycbacterium avium complex Antimicrob Agents Chemother 1991; 35: 462-470.
33. Inderlied CB, Barbara BL, Wu M, Young LS, Bermudez LEM. Activities of the benzoxazinorfamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrob Agents Chemther 1994; 38: 1838-1843.
34. Watt B. in vitro Sensitivities and treatment of less common Mycobacteria. J Antimicrob Agents Chemther 1997; 39: 567-574.
35. Bryskier A, Butzler JP. Macrolides. In: In: O'Grady F, Lambert HP, Finch RG, Greenwood D, editors. In: Antibiotics and Chemotherapy. Edinburg: Churchil Living stone 1997; 377-393.
36. Casal K guitierrrez J, Gonzalez J, Ruiz P. in-vitro Susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotics R 28965. Tubercle 1987; 68: 141-143.
37. Brown BA, Wallace RJ, Onyi GO, de Rosas V. Activity of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae and M. Chelonae like organisms. Antimicrob Agents Chemther 1992; 36: 180-184.
38. Rastogi N, Goh KS, Bryskier A. in vitro Activity of roxithromycin against 16 species of a typical mycobacteria and effect of pH on its radiometric MICs. Antimicrob Agents Chemther 1993; 37: 1560-1562.
39. Winder FG, Collins PB, Whelan D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J Gen Microbiol 1997; 66: 379-380.
40. Phetsuksiri B, Jackson K Scherman H, Mc Neil M, Baulard AR, Slayden RA, De Barber AE, Barry CE, baired MS, Brennan PJ. Unique mechanism of action of the thiourea drug isoxylon Mycobacterium tuberculosis. J Biol Chem 2003; 278(52): 53123-53130.
41. Phetusksiri B, Baulard AR, et al. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemther 1999; 43 (5): 1042-1051.
42. Trinka L, Mison P. Drugs and treatment regimens, 1. paminosalicylic acid (PAS). In: Bartment K, editor. Antituberculosis drugs, handbook of experimental pharmacology, Berlion, Springer-Verlag 1998; 51-68.
43. Cyanamon MH, Klemmens SP. Antimycobacterial activity of a series of pyrazinoic acid esters. J Med Chem 1982; 35: 1212-1215.
44. Otten H. Experimental evaluation of efficacy V11 cycloserine (Cs) and terizidone (TZ). In: Bartman K, editor. Antituberculosis drugs Handbook of Experimental Pharmacology, Berlin, Springer Verlog 1988; 158-166.
45. David HL, Takayama K, Goldman DS. Susceptibility of mycobacterial D-alnyl-D-alanine synthetase to D-cycloserine. Am Rev Resp Dis 1969; 100: 579-581.
46. Cacers NE, Harrris NB, Wellehen JF, Feng Z, Kapoor V, Barletta RG. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bateriol 1997; 179: 5046-5055.
47. Tumbanatham A, Vinodkumar S. Ofloxacin induced orthropathy in patients with multi-drug resistance tuberculosis. J Assoc Physicians India 2003; 48 (6): 647-648.
48. Albrecht R. Development of antibacterial agents of the nalidixic acid type. Prog Drug Res 1877; 21: 9-104.
49. Wolfson JS, Hooper DC. The floroquinolones: structures, mechanism of action and resistance and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28: 581-586.
50. Kremer I, Douglas JD, Morehouse C, et al. Thiolactomycin and related analogs as novel antimycobacterial agents targeting Kas A and Kas B condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 2000; 275: 16857.
51. Mitscher LA, Baker W. Tuberculosis: A search for novel therapy starting with natural products. Med Res rev 1998; 18 (6): 363-374.
52. Field SK, Cowie RL. Treatment of Mycobacterium avium intracellular complex lung disease with a macrolide, ethambvutol and clofamine. Chest 2003; 124 (4): 1482-1796.
53. Reddy VM, Srinivasan S, Gangadhram PR. invitro and in vivo Synergestic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC). Tuber Lung Dis 1994; 75(3): 208-212.
54. Reddy VM, Nadadhur G, Daneluzzi D, O' Sullivian JF, Gangadharan PR. Antituberculosis activity of clofazimine and its new analoge B4154 and 64157. Antimicrob Agents Chemother 1996; 40 (3): 633-636.
55. Agrawal KC, Bears KB, Shegal RK. Potential radiosensitizing agents dinitroimidazoles. J Med Chem 1979; 22: 583-586.
56. Nagarjan & Shumkar RG, Rajjapa S, Shenoy SJ, Costa-perira R. Nitroimidazole XX1-2,3-dihydro-6-imidazo[2,1-b]oxazDlcs with antitubercular activity. Eur J Med Chem 1989; 24: 631-633.
57. Eustic DC, Feldman PA, Zajac I, Sloe AM. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988; 32: 1218.
58. Bakkestuen AK, Gundersen LL, Langi G, Liu F, Nolsoe JM. 9-Benzyl purines with inhibitory activity against Mycobacterium tuberculosis. Bio-org Med Chem Lett 2000; 10: 1207.
59. Gundersen LL, Meyer JN, Spilsberg B. Synthesis and antimy-cobacterial activity of 6-atyl purines: The requirements for the N-(-substituted in active antimycobacterial purities. J Med Chem 2002; 45: 1383-1386.
60. Scozzafava A, Mastrolorenzo A, Spuran CT. Antimycobacterial activity of 9-sulfonated/sulfenyllated-6-mercaptopurine derivatives. Bioorg Med Chem Lett 1998; 11: 1675-1678.
61. Eratan M, Bilgin AA, Palaska E, Yulung N. Sysnthesis and antifungal activity of some 3-(2-phynylethyl)-5-subsiituted tetrahydro 2H- 1,3,5- thiadiazine-2-thiones. Arzne Fotsch/drug Res 1992; 42 (1):160.
62. Zsolnai VT. Die intiraikrobielle wirkung - von potentiellen isothiocynate- bildnern. Arzne Forsch/Drug Res 1968; 18: 1319-1324.
63. Madry JA, Bansal N, Bermudez. LE, et al. Homologoted aza analogs of arabinose as antimycobacterial agents. Bioorg Med Chem Lett 1998; 8: 237-342.
64. Tripathi RP, Rastogi SK, Kundu B, et al. identification of inhibitors of DNA topoisomerase II from a synthetic library of glycoconjugates. Comb Chem Highthrough screen 2001; 4: 237-244.
65. Ze Qi Xu, Liu YM, Flavin M. Preparation of calanolide analogs, for treating and preventing tuberculosis. Chem Abstract 2000; 132: 293599.
66. Grange J, Snell N. Activity of bromhexine and ambroxol, semi-synthetic derivatives of vasicine from the India shrub adhtoda vasica, against Mycobacterium tuberculosis in vitro. J Ethnopharmacol 1996; 50:49-53.
67. Dymock W, Warden C, Hooper D. In: A history of the principal drugs of vegetable origin met within a british india, pharmacographia indica. Trubner and Co 1893; 18: 49-51.
68. Mitscher LA, Gollapudi SR, Oburn DS, Drake S. Antimycrobial agents from higher plants:Two dimethylebenzisochromans from karawinskia humboldtiana. Phytochemistry 1985; 24:1681-1683.
69. Wachter GA, Franzblau SG, Montenegro G. A new antitubercular mulanine, diterpenoid from Azorella madreporica. Clos J Nat Prod 1998; 61: 965-968.
70. McCutcheon AR, Stokes RW, Thorson LM, Ellis SM, Hancock REW, Towers GHN. Antimycobacterial screening of British Columbian medicinal plants. Int J Pharmacon 1999; 35: 77-83
71. Kobaisy M, Abramowski Z, Lermer L, Saxena G, Hancock REW, Towers GHN. Antimycobacterial Polyenes of Devil's Club (Oplopansz horridus), a North American, native medicinal plant. J Nat Prod 1997; 60: 120-1213.
72. Chang MW, Tasaka H, Kuwbara M, Watanabe T, Matsuo Y. Effects of panax ginseng on the growth of Mycobectarium tuberculosis H37Rv. Hiroshima J Med Sci 1979; 28: 115-118.
73. Rastogi N, Abaul J, Goh KS, Devallois A, Philogen E, Bourgeois P. Antimicrobial activity of chemically define natural substances from Caribben flora in Guadeloupe. FEMS Immunol Med Microbiol 1998; 20: 267-273.
74. Grange JM, Davey RW. detection of antituberculous activity in plant extracts. J Appl Bacteriol 1990; 68: 587-591.
75. Lucas EH, Lickfeldt A, Gottshall RY, Jennings JC. The occurance of antibacterial substances in seed plants With special reference to Mycobacterium tuberculosis. Bull Torrey Club 1951; 78: 310-321.
76. Van PL, Pagezy H, Kayonga A. Plantes medicinales et toxiques du Rwansa (1). Afrique Medical 1975; 14: 925-930.
77. Cantrell CL, Lu T, Fronczek FR, Fischer NH, Adams LB, Franzblau SG Antimycobacterial cycloartanase from Borrichia frutescens. J Nat Prod 1996; 59: 1131-1136.
78. Lu T, Cantrell CL, Robbos SI, Franzblau SG, Fischer NH. Antimycobacterial matricaria ester and lactones from asteree species. Planta Med 1999; 64: 665-667.
79. Wang VHL. in-vitro Antibacterial activity of some common Chinese herbs on Mycobacteril tuberculosis. Chi Med J (Engl) 1950; 68: 169-172.
80. Lu T, Vargas D, Franzblau SG, Fischer NH. Diterpenes from Solidago rugosa. Phytochemistry 1995; 38: 451-456.
81. Cantrell CL, Fischer NH, Urbatsch L, McGuire MS, Franzblau SG. Antimycobacterial crude plan extracts from South, Central, and North America. Phytomedicine 1988; 5: 137-145.
82. Fabry W, Okemo PO, Ansorg R. Antibacterial aictivity of Eaxt African medicinal plants. J Ethnopharmacol 1988; 60: 79-94.
83. Ingolfsdottir K, Chung GAC, Skulason VG, Gissurarson SR, Vilhelmsdottir M. Antimicrobial activity of lichen metabolites in vitro. Eur J Pharm Sci 1998; 6: 92-96.
84. Muhammad I, Moosa JS, El-Feraly FS. Additional anti bacterial diterpenes from the bark of Juniperus excelsa M Bieb Phytother Res 1992; 6: 261-264.
85. Muhammad I, Moosa JS, El-Feraly FS. Additional anti bacterial diterpenes from the bark of Juniperus excelsa. M Bieb Phytother Res 1996; 10: 604-607.
86. Fitzpatrick F. Plant substances active against Mycobacterium tuberculosis. Antobiot Chemother 1954; 4: 529-536.
87. Ghosal S, Chaudbri RK. Chemical constituents of Gentianaceae XVI: antitubercular activity of xanthones of Canscora decussate schult. J Phar Sci 1975; 64: 888-989.
88. Gabbrielli G, Loggini F, Cioni PL, Giannaccini B, Mancuso E. Activity of lavandino essential oil against non-tubercular rapid grown mycobacteria. Pharmacol Res Commun1988; 20 (Suppl.5), 37-40.
89. Rajab MS, Cantrell CL, Franzblau. SG, Fischer NH. Antimicrobial activity of (E) Phytol and derivatives:A preliminary structure activity study. Planta Med 1998; 64: 2-4.
90. Ulubelen A, Topcu G. Bozok JC. Norditarpenoids and diterpenoids from Salvia multicaulis with antituberculous activity. J Nat Prod 1997; 60:1275-1280.
91. Gottshall RY, Lucas EH, Lickfedt A, Roberts JM. The occurance of antibacterial substances active against Mycobacterium tuberculosis in seed plants. J Clin Invest 1949; 28: 920-921.
92. Mitscher LA, Baker WR. Tuberculosis: A search for novel therapy starting with natural products. Med Res Rev 1998; 18: 363-374.
93. Jain RC. Anti-tubercular activity of garlic oil. Indian J Pathol Micrbiol 1998; 41:131.
94. Delaha EC, Garagusi VF. Inhibition of mycobacteria, by garlic exiact ( Allium sativum). Antimicrob Agents Chemother 1985; 27: 485-486.
95. Abbruzzese MR, Delaha EC, Garagousi VF. Absence of antimycobacterial synergism between garlic extract and antituberculosis drug. Diag Microbiol Infect Dis 1987, 9: 79-95.
96. Moreira RRD, Anno IS, Leite CQF. Sensitivity of microbacteria to different species of Eucalyptus L'Herit. Rev Microbiol 1997; 28: 256-260.
97. Leite CQF, Moreira RRD, Neto JJ. In: Action of eucalyptus oils against Mycobacterium avium Fitoterapia LXIX 1998; 282-283.
98. Roper R, Ma TS. In Microchemical investigation of medicinal plants II The antitubercular activity of some plants acids and their hydrazides. Mikrochimica Acta (Wien) 1968; 212-218.
99. Ma TS, Roper R. In: Microchemical investigation of medicinal plants.1. The antitubercular principle in Prunus mume and Schizoandra chinensis, Mikrochimica Acta (Wien) 1968; 167-181.
100. Houghton PJ, Woldemariam. TZ, Watanabe Y, Yates M. Activity against Mycobacterium tuberculosis of alladoid constituents of angostura bark, Galipea Officinalis. Planta Med 1999; 65: 250-254.
101. Gentry EJ. Jampani HB, Keshavarg-Shokri A. Antitubercular natural products: Barberine from the root of commercial Hydrastis canadensis powder. Isolation of anactive 8-oxotetrahydrothalifendine, canadine, beta hydrastine and two new quinic acid esters, hycandinic acid ester-1 and 2. J Nat Prod1998; 61: 1187-1193.
102. Rabman S, Fukamiya N, Okano M, Tagahara K, Lee KH. Antituberculosis activity of quassinoids. Chem Pharm Bull 1997; 45: 1527-1529.
103. Hiserodt RD, Franzblau SG, Rosen RT. Isolation of 6-,8-, and 10-gingerol from ginger rhizome by HPLC and preliminary evaluation of Mycobacterium avium and Mycobacterium tuberculosis. J Agric Food Chem 1998; 46: 2504-2508.
104. Nathan, C., Lima, C.D., Bryk, R.: US20070202118 (2007).